Streetbeat News

Partnerships

RANI

Rani Therapeutics (NASDAQ:RANI) has expanded its partnership with Celltrion to develop RT-105, an orally administered adalimumab biosimilar. This follows their initial collaboration for the development of RT-111, an orally administered ustekinumab biosimilar, announced in January.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:07 pm

CYTH

RFL

Cyclo Therapeutics has executed a definitive agreement with Rafael Holdings for a $5 million private placement. This will provide additional funding for the company's ongoing operations.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:06 pm

MRK

MRNA

Moderna and Merck announced that their mRNA-4157 (V940) in combination with KEYTRUDA showed a statistically significant and clinically meaningful improvement in distant metastasis-free survival in high-risk stage III/IV melanoma patients.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:06 pm

NVAX

Novavax has announced an agreement with the Bill & Melinda Gates Medical Research Institute to include its Matrix-M adjuvant as a potential component in vaccine research. This collaboration aims to enhance the effectiveness of vaccines in development.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:05 pm

DB

DSEEY

JPM

MUFG

SFTBF

Daiwa Securities Group has allowed nearly 9,000 employees in Japan to use AI-powered chatbot ChatGPT, aiming to streamline retail business and improve efficiency. Other financial institutions, such as Deutsche Bank, JP Morgan, Softbank Group, and Mitsubishi UFJ Financial Group, are also exploring AI applications.

Portfolio Pulse from Anusuya Lahiri

June 05, 2023 | 11:42 am

ATVI

MSFT

SONY

TCEHY

Sony plans to explore streaming game options and leverage its AI agent GT Sophy to enhance cloud gaming, but CEO Kenichiro Yoshida warns of latency and costly inefficiencies. Microsoft's $75 billion Activision Blizzard takeover deal has intensified the competition between the two companies.

Portfolio Pulse from Anusuya Lahiri

June 05, 2023 | 11:33 am

ENTG

ESI

Entegris and Element Solutions have terminated their distribution agreement, with Entegris receiving $200 million in exchange for ending the exclusive distribution of ViaForm Copper Damascene products.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:32 am

MNMD

Numinus Wellness announced that Cedar Clinical Research (CCR), a subsidiary of Numinus, has been selected as a top research site for MindMed's Phase 2b study evaluating MM-120. This partnership will advance the development of psychedelic-assisted therapies.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:18 am

NRXP

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen Inc. have announced a collaboration to develop and commercialize NRX-101, with NRx eligible to receive up to $330 million in milestone payments. Lotus will acquire worldwide rights for NRX-101 for S-TRBD.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:13 am

BVXV

BiondVax has signed an exclusive worldwide license agreement to develop and commercialize a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:11 am